




Instance: composition-en-987766e2219c5177d278b3430b3652be
InstanceOf: CompositionUvEpi
Title: "Composition for orgovyx Package Leaflet"
Description:  "Composition for orgovyx Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpba62682d7a134bf3f9e55395558b6846)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - orgovyx"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Orgovyx is and what it is used for  </li>
<li>What you need to know before you take Orgovyx  </li>
<li>How to take Orgovyx </li>
<li>Possible side effects  </li>
<li>How to store Orgovyx  </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What orgovyx is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What orgovyx is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Orgovyx contains the active substance relugolix. It is used for the treatment of adult patients with 
advanced prostate cancer who respond to hormone therapy. </p>
<p>Relugolix works by blocking a step in the process that signals the testes to produce testosterone (the 
male sex hormone). As testosterone can stimulate the growth of prostate cancer, by decreasing it to 
very low levels, relugolix prevents prostate cancer cells from growing and dividing.  </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take orgovyx"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take orgovyx"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Orgovyx 
- if you are allergic to relugolix or any of the other ingredients of this medicine (listed in 
section 6).  </p>
<p>Warnings and precautions<br />
Talk to your doctor or pharmacist before taking Orgovyx if you have any of the following:</p>
<ul>
<li>Heart circulation conditions such as heart rhythm problems (arrhythmia). The risk of heart 
rhythm problems may be increased when using Orgovyx. Your doctor may check your body 
salts (electrolytes) and the electrical activity of your heart during treatment with Orgovyx.  </li>
<li>Tell your doctor right away if you get any signs or symptoms like dizziness, fainting, feeling 
that your heart is pounding or racing (palpitations) or chest pain. Those can be symptoms of 
serious heart rhythm problems. </li>
<li>Liver disease. Liver function may need to be monitored. Use of Orgovyx has not been 
investigated in patients with severe liver disease. </li>
<li>Renal (kidney) disease. </li>
<li>Osteoporosis or any condition that affects the strength of your bones. Reduced levels of 
testosterone may lead to thinning of bones. </li>
<li>Monitoring of your disease with a blood test for prostatespecific antigen (PSA). </li>
</ul>
<p>Children and adolescents 
Orgovyx is not for use in children and adolescents under 18 years of age. </p>
<p>Other medicines and Orgovyx 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines, including medicines obtained without a prescription. </p>
<p>Orgovyx may interfere with some medicines used to treat heart rhythm problems (e.g. quinidine, 
procainamide, amiodarone and sotalol) or might increase the risk of heart rhythm problems when used 
with some other drugs (e.g. methadone [used for pain relief and part of drug addiction detoxification], 
moxifloxacin [an antibiotic], antipsychotics used for serious mental illnesses).  </p>
<p>Other medicines may interfere with the absorption of relugolix, resulting in either an increase in blood 
levels that may increase side effects or decrease in blood levels that may decrease the effectiveness of 
Orgovyx. Examples of medicines that may interfere with Orgovyx include:</p>
<ul>
<li>Certain medicines used to treat epilepsy (e.g. carbamazepine, phenytoin, phenobarbital). </li>
<li>Certain medicines used to treat bacterial infections (e.g. rifampicin, azithromycin, 
erythromycin, clarithromycin, gentamicin, tetracycline).  </li>
<li>Certain medicines used to treat fungal infections (e.g. ketoconazole, itraconazole). </li>
<li>Certain medicines used to treat prostate cancer (e.g. apalutamide). </li>
<li>Herbal remedies containing St John s Wort (Hypericum perforatum).   </li>
<li>Certain medicines used to treat high blood pressure (e.g. carvedilol, verapamil). </li>
<li>Certain medicines used to treat arrhythmias (e.g. amiodarone, dronedarone, propafenone, 
quinidine). </li>
<li>Certain medicines used to treat angina (e.g. ranolazine). </li>
<li>Certain medicines used as immunosuppressants (e.g. cyclosporine). </li>
<li>Certain medicines used to treat HIV infections (e.g. ritonavir [or ritonavir-containing 
combinations], efavirenz). </li>
<li>Certain medicines used to treat hepatitis C (e.g. telaprevir). </li>
</ul>
<p>Your doctor may therefore change your medications, change when you take your certain medications, 
the dose of the medicines, or increase the dose of Orgovyx. </p>
<p>Pregnancy, breast-feeding, and fertility 
Orgovyx is intended for use in men with prostate cancer. This medicine could possibly have an effect 
on male fertility.<br />
This medicine is not indicated in women who could become pregnant. It is not used in women who 
are, or may be pregnant or breast-feeding.  </p>
<ul>
<li>
<p>Information for men:</p>
</li>
<li>
<p>If you are having sex with a woman who can become pregnant, use a condom and another 
effective birth control method used by your partner, during treatment and for 2 weeks 
after treatment with this medicine, to prevent pregnancy.  </p>
</li>
<li>If you are having sex with a pregnant woman, use a condom to protect the unborn child. </li>
</ul>
<p>Driving and using machines 
Tiredness and dizziness are very common (tiredness) and common (dizziness) side effects that may 
impair your ability to drive and use machines. These side effects may be due to the treatment or effects 
resulting from the underlying disease. </p>
<p>Orgovyx contains sodium 
This medicine contains less than 1 mmol sodium (23 mg) per film-coated tablet, that is to say 
essentially  sodium-free . </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take orgovyx"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take orgovyx"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist 
if you are not sure.  </p>
<p>The recommended dose is:<br />
<em> three tablets on the first day of treatment.<br />
</em> one tablet once a day after that, taken around the same time each day. 
Your doctor may change your dose if needed. </p>
<p>Swallow whole. The tablets can be taken with or without food with some liquid.  </p>
<p>If you take more Orgovyx than you should 
There have been no reports of serious harmful effects from taking several doses of this medicine at 
once. If you have taken too many Orgovyx tablets, or you discover that a child has taken some, talk to 
your doctor as soon as possible. Bring the medicine to show the doctor.  </p>
<p>If you forget to take Orgovyx 
If you remember missing a dose less than 12 hours after the usual time you would have taken it, take it 
as soon as you remember and then carry on taking your next tablets at the next days as usual. If you 
miss a dose by more than 12 hours, do not take the dose. Just take your next dose the following day as 
usual.  </p>
<p>If you stop taking Orgovyx 
If you would like to stop taking this medicine, talk to your doctor first. Your doctor will explain the 
effects of stopping treatment and discuss other possibilities with you.  </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Some side effects could be serious. 
Seek urgent medical attention if you develop:</p>
<ul>
<li>Rapid swelling of your face, mouth, lips, tongue, throat, abdomen, or arms and legs 
(angioedema) (uncommon: may affect up to 1 in 100 people). </li>
</ul>
<p>The following side effects have been reported with Orgovyx and are listed below according to the 
frequency with which they occur.  </p>
<p>Very common (may affect more than 1 in 10 people):</p>
<ul>
<li>hot flush </li>
<li>diarrhoea </li>
<li>constipation  </li>
<li>muscle and joint pain </li>
<li>tiredness </li>
</ul>
<p>Common (may affect up to 1 in 10 people):</p>
<ul>
<li>low red cell count (anaemia) </li>
<li>breast enlargement in men (gynaecomastia)  </li>
<li>sleeplessness </li>
<li>depression </li>
<li>dizziness </li>
<li>headache </li>
<li>high blood pressure </li>
<li>upset stomach including feeling sick (nausea) </li>
<li>increased sweating  </li>
<li>rash </li>
<li>decreased interest in sex </li>
<li>increased weight  </li>
<li>increased blood sugar levels </li>
<li>increased blood fat (triglyceride) levels </li>
<li>increased blood cholesterol level </li>
</ul>
<p>Uncommon (may affect up to 1 in 100 people):</p>
<ul>
<li>thinning of the bones (osteoporosis) </li>
<li>increased liver enzymes  </li>
<li>hives (urticaria) </li>
</ul>
<p>Rare (may affect up to 1 in 1,000 people):</p>
<ul>
<li>heart attack </li>
</ul>
<p>Not known (frequency cannot be estimated from the available data):</p>
<ul>
<li>changes in the electrocardiogram (QT prolongation) </li>
</ul>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system listed 
in Appendix V. By reporting side effects, you can help provide more information on the safety of this 
medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store orgovyx"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store orgovyx"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the outer carton and the bottle label 
after EXP. The expiry date refers to the last day of that month. </p>
<p>This medicine does not require any special storage conditions. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Orgovyx contains<br />
- The active substance is relugolix.<br />
- The other ingredients are mannitol (E421), sodium starch glycolate (E468), hydroxypropyl 
cellulose (E463), magnesium stearate (E572), hypromellose (E464), titanium dioxide (E171), 
iron oxide red (E172), carnauba wax (E903).  </p>
<p>See  Orgovyx contains sodium  in section 2 for more information. </p>
<p>What Orgovyx looks like and contents of the pack 
Orgovyx film-coated tablets are light red, almond-shaped, film-coated tablets (11 mm [length]   8 mm 
[width]) with  R  on one side and  120  on the other side. Orgovyx is available in a plastic white 
bottle containing 30 film-coated tablets, in pack sizes of 30 film-coated tablets and 90 film-coated 
tablets (3 bottles of 30 film-coated tablets). Each bottle also contains a desiccant to help to keep your 
medicine dry (protect it from moisture), do not remove the desiccant from the bottle. Each bottle is 
enclosed with an induction-sealed, child-resistant cap.<br />
Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder<br />
Accord Healthcare S.L.U. 
World Trade Center, Moll de Barcelona, s/n, 
Edifici Est 6  planta, 
08039 Barcelona, 
Spain </p>
<p>Manufacturer 
Accord Healthcare Polska Sp.z o.o., 
ul. Lutomierska 50,95-200 Pabianice, Poland </p>
<p>Accord Healthcare B.V.,<br />
Winthontlaan 200,<br />
3526 KV Utrecht,<br />
The Netherlands  </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>AT / BE / BG / CY / CZ / DE / DK / EE / FI / FR / HR / HU / IS / IT / LT / LV / LX / MT / NL / NO 
/ PT / PL / RO / SE / SI / SK / UK(NI) / ES 
Accord Healthcare S.L.U. 
Tel: +34 93 301 00 EL 
Win Medica Pharmaceutical S.A.<br />
Tel: +30 210 7488 This leaflet was last revised in </p>
<p>Other sources of information </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-987766e2219c5177d278b3430b3652be
InstanceOf: CompositionUvEpi
Title: "Composition for orgovyx Package Leaflet"
Description:  "Composition for orgovyx Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpba62682d7a134bf3f9e55395558b6846)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - orgovyx"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen </p>
<ol>
<li>Virkning og anvendelse </li>
<li>Det skal du vide, før du begynder at tage Orgovyx </li>
<li>Sådan skal du tage Orgovyx </li>
<li>Bivirkninger </li>
<li>Opbevaring </li>
<li>Pakningsstørrelser og yderligere oplysninger </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What orgovyx is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What orgovyx is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Orgovyx indeholder det aktive stof relugolix. Det anvendes til behandling af voksne patienter med 
fremskreden hormonfølsom prostatakræft, som reagerer på hormonbehandling. </p>
<p>Relugolix virker ved at blokere et trin i den proces, som sender signal til testiklerne om at producere 
testosteron (det mandlige kønshormon). Da testosteron kan stimulere væksten af prostatakræft, kan 
relugolix takket være den kraftige reduktion af testosteronniveauet forhindre prostatakræftcellerne i at 
vokse og dele sig. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take orgovyx"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take orgovyx"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Orgovyx 
- hvis du er allergisk over for relugolix eller et af de øvrige indholdsstoffer i Orgovyx (angivet i 
punkt 6). </p>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen eller apotekspersonalet, før du tager Orgovyx, hvis noget af følgende gælder for dig:</p>
<ul>
<li>Du har en kredsløbssygdom, f.eks. problemer med hjerterytmen (arytmi). Når du bruger 
Orgovyx, kan det øge risikoen for problemer med hjerterytmen. Din læge vil muligvis 
kontrollere din krops indhold af forskellige salte (elektrolytter) og dit hjertes elektriske aktivitet 
under behandlingen med Orgovyx. </li>
<li>Fortæl det straks til lægen, hvis du oplever tegn eller symptomer som svimmelhed, besvimelse, 
en følelse af, at dit hjerte banker meget hårdt eller hurtigt (palpitationer), eller smerter i brystet. 
Dette kan være symptomer på alvorlige problemer med hjerterytmen. </li>
<li>Leversygdom. Det kan være nødvendigt at overvåge leverfunktionen. Brugen af Orgovyx er 
ikke blevet undersøgt hos patienter med svær leversygdom. </li>
<li>Nyresygdom. </li>
<li>Knogleskørhed (osteoporose) eller andre tilstande, som påvirker knoglestyrken. Nedsatte 
testosteronniveauer kan føre til tab af knoglemasse. </li>
<li>Din sygdom bliver overvåget med en blodprøve for prostataspecifikt antigen (PSA). </li>
</ul>
<p>Børn og unge 
Orgovyx er ikke beregnet til brug hos børn og unge under 18 år. </p>
<p>Brug af anden medicin sammen med Orgovyx 
Fortæl det altid til lægen eller apotekspersonalet, hvis du tager anden medicin, for nylig har taget 
anden medicin eller planlægger at tage anden medicin. Dette gælder også medicin, som ikke er købt 
på recept. </p>
<p>Orgovyx kan påvirke visse lægemidler, der bruges til behandling af hjerterytmeproblemer (f.eks. 
quinidin, procainamid, amiodaron og sotalol), og kan øge risikoen for hjerterytmeproblemer, når det 
anvendes sammen med visse andre lægemidler (f.eks. methadon [til smertelindring og som en del af 
afvænningsbehandlingen ved stof- eller medicinmisbrug], moxifloxacin [et antibiotikum] eller 
antipsykotiske lægemidler, der anvendes ved alvorlig mental sygdom). </p>
<p>Andre lægemidler kan påvirke absorptionen af relugolix og enten føre til en stigning i indholdet i 
blodet, hvilket kan give flere bivirkninger, eller et fald i indholdet i blodet, hvilket kan reducere 
Orgovyx' effektivitet. Eksempler på lægemidler, som kan påvirke Orgovyx, omfatter:</p>
<ul>
<li>Visse lægemidler, der bruges til behandling af epilepsi (f.eks. carbamazepin, phenytoin, 
phenobarbital). </li>
<li>Visse lægemidler, der bruges til behandling af bakterieinfektioner (f.eks. rifampicin, 
azithromycin, erythromycin, clarithromycin, gentamicin, tetracyclin). </li>
<li>Visse lægemidler, der bruges til behandling af svampeinfektioner (f.eks. ketoconazol, 
itraconazol). </li>
<li>Visse lægemidler, der bruges til behandling af prostatakræft (f.eks. apalutamid). </li>
<li>Naturmedicin, der indeholder perikon (Hypericum perforatum). </li>
<li>Visse lægemidler, der bruges til behandling af højt blodtryk (f.eks. carvedilol, verapamil). </li>
<li>Visse lægemidler, der bruges til behandling af uregelmæssige hjerteslag (f.eks. amiodaron, 
dronedaron, propafenon, quinidin). </li>
<li>Visse lægemidler, der bruges til behandling af angina pectoris (f.eks. ranolazin). </li>
<li>Visse lægemidler, der bruges til at undertrykke immunsystemet (f.eks. ciclosporin). </li>
<li>Visse lægemidler, der bruges til behandling af hiv-infektioner (f.eks. ritonavir [eller 
kombinationer, der indeholder ritonavir], efavirenz). </li>
<li>Visse lægemidler, der bruges til behandling af leverbetændelse (hepatitis C) (f.eks. telaprevir). </li>
</ul>
<p>Din læge kan derfor give dig andre lægemidler, ændre det tidspunkt, hvor du skal tage visse 
lægemidler, doserne af lægemidlerne eller øge din dosis af Orgovyx. </p>
<p>Graviditet, amning og frugtbarhed 
Orgovyx er beregnet til brug hos mænd med prostatakræft. Lægemidlet kan muligvis have en 
indvirkning på mandlig frugtbarhed. 
Lægemidlet er ikke indiceret til kvinder, som kan blive gravide. Det anvendes ikke til kvinder, som er 
gravide eller kan være gravide, eller til kvinder, som ammer. </p>
<ul>
<li>
<p>Oplysninger til mænd:</p>
</li>
<li>
<p>Hvis du har samleje med en kvinde, som kan blive gravid, skal du bruge kondom, og din 
partner skal anvende en anden form for sikker prævention, mens du er i behandling og i 
2 uger efter behandlingen med denne medicin for at undgå graviditet. </p>
</li>
<li>Hvis du har samleje med en gravid kvinde, skal du bruge kondom for at beskytte det 
ufødte barn. </li>
</ul>
<p>Trafik- og arbejdssikkerhed 
Træthed er en meget almindelig bivirkning, og svimmelhed er en almindelig bivirkning, som begge 
kan svække din evne til at køre bil og betjene maskiner. Disse bivirkninger kan skyldes behandlingen 
eller opstå på grund af din underliggende sygdom. </p>
<p>Orgovyx indeholder natrium 
Dette lægemiddel indeholder mindre end 1 mmol natrium (23 mg) pr. filmovertrukket tablet, dvs. det 
er i det væsentlige natriumfrit. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take orgovyx"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take orgovyx"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens anvisning. Er du i tvivl, så spørg lægen eller 
apotekspersonalet. </p>
<p>Den anbefalede dosis er: </p>
<ul>
<li>
<p>tre tabletter på førstedagen af behandlingen. </p>
</li>
<li>
<p>én tablet én gang dagligt derefter, som skal tages på cirka samme tidspunkt hver dag. 
Din læge kan ændre din dosis, hvis det bliver nødvendigt. </p>
</li>
</ul>
<p>Synkes hele. Tabletterne kan tages med eller uden mad og med en smule væske. </p>
<p>Hvis du har taget for meget Orgovyx 
Der har ikke været rapporteret om alvorlige bivirkninger efter indtagelse af adskillige doser samtidigt 
af dette lægemiddel. Hvis du har taget for mange Orgovyx-tabletter, eller hvis du opdager, at et barn 
har taget nogle tabletter, skal du tale med lægen hurtigst muligt. Tag medicinen med, så du kan vise 
den til lægen. </p>
<p>Hvis du har glemt at tage Orgovyx 
Hvis du kommer i tanke om, at du har glemt at tage en dosis, mindre end 12 timer efter det normale 
tidspunkt, hvor du skulle have taget den, skal du tage den, så snart du kommer i tanke om det, og 
derefter fortsætte med at tage de næste tabletter som normalt i dagene derefter. Hvis du kommer i 
tanke om en glemt dosis, når der er gået mere end 12 timer, siden du skulle have taget den, må du ikke 
tage den glemte dosis. Du skal blot tage din næste dosis som normalt dagen efter. </p>
<p>Hvis du holder op med at tage Orgovyx 
Hvis du ønsker at holde op med at tage dette lægemiddel, skal du først tale med din læge. Lægen vil 
forklare virkningen af at stoppe behandlingen og diskutere andre muligheder med dig. </p>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Nogle bivirkninger kan være alvorlige. </p>
<p>Søg atraks lægehjælp, hvis du får:</p>
<ul>
<li>Akut hævelse af ansigt, mund, læber, tunge, svælg, mave eller arme og ben (angioødem) (ikke 
almindelig: kan forekomme hos op til 1 ud af 100 personer). </li>
</ul>
<p>Følgende bivirkninger er blevet rapporteret med Orgovyx og er anført herunder i henhold til den 
hyppighed, hvormed de kan forekomme. </p>
<p>Meget almindelige (kan forekomme hos flere end 1 ud af 10 personer):</p>
<ul>
<li>hedeture </li>
<li>diarré </li>
<li>forstoppelse </li>
<li>muskel- og ledsmerter </li>
<li>træthed </li>
</ul>
<p>Almindelige (kan forekomme hos op til 1 ud af 10 personer):</p>
<ul>
<li>lavt antal røde blodlegemer (blodmangel/anæmi) </li>
<li>forstørrelse af brystvæv hos mænd (gynækomasti) </li>
<li>søvnløshed </li>
<li>depression </li>
<li>svimmelhed </li>
<li>hovedpine </li>
<li>højt blodtryk </li>
<li>maveproblemer, herunder kvalme </li>
<li>øget svedtendens </li>
<li>udslæt </li>
<li>nedsat sexlyst </li>
<li>vægtforøgelse </li>
<li>forhøjet blodsukker </li>
<li>forhøjet indhold af fedt (triglycerider) i blodet </li>
<li>forhøjet kolesterol </li>
</ul>
<p>Ikke almindelige (kan forekomme hos op til 1 ud af 100 personer):</p>
<ul>
<li>tab af knoglemasse (osteoporose) </li>
<li>forhøjede leverenzymer </li>
<li>nældefeber (urticaria) </li>
</ul>
<p>Sjældne (kan forekomme hos op til 1 ud af 1000 personer):</p>
<ul>
<li>hjerteanfald </li>
</ul>
<p>Ikke kendt (hyppigheden kan ikke estimeres ud fra forhåndenværende data):</p>
<ul>
<li>ændringer i elektrokardiogram (QT-forlængelse) </li>
</ul>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge eller apotekspersonalet. Dette gælder også 
mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også 
indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i 
Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information 
om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store orgovyx"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store orgovyx"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på den ydre karton og på beholderens etiket efter 
EXP. Udløbsdatoen er den sidste dag i den nævnte måned. </p>
<p>Dette lægemiddel kræver ingen særlige forholdsregler vedrørende opbevaringen. </p>
<p>Spørg apotekspersonalet, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke 
smide medicinrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Orgovyx indeholder:</p>
<ul>
<li>Aktivt stof: relugolix. </li>
<li>Øvrige indholdsstoffer: mannitol (E421), natriumstivelsesglycolat (E468), 
hydroxypropylcellulose (E463), magnesiumstearat (E572), hypromellose (E464), titandioxid 
(E171), rød jernoxid (E172), carnaubavoks (E903). </li>
</ul>
<p>Se "Orgovyx indeholder natrium" i punkt 2 for at få flere oplysninger. </p>
<p>Udseende og pakningsstørrelser 
Orgovyx filmovertrukne tabletter er lyserøde, mandelformede, filmovertrukne tabletter 
(11 mm [længde] × 8 mm [bredde]) med "R" på den ene side og "120" på den anden side. Orgovyx 
leveres i en hvid plastbeholder med 30 filmovertrukne tabletter, i pakninger med 30 filmovertrukne 
tabletter og 90 filmovertrukne tabletter (3 beholder med 30 filmovertrukne tabletter). Hver beholder 
indeholder også et tørremiddel, der hjælper med at holde lægemidlet tørt (beskytte det mod fugt). 
Fjern ikke tørremidlet fra beholderen. Hver beholder er lukket med et induktionsforseglet, børnesikret 
låg. 
Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen 
Accord Healthcare S.L.U. 
World Trade Center, Moll de Barcelona, s/n, 
Edifici Est 6ª planta, 
08039 Barcelona, 
Spanien </p>
<p>Fremstiller 
Accord Healthcare Polska Sp.z o.o., 
ul. Lutomierska 50,95-200 Pabianice, Polen </p>
<p>Accord Healthcare B.V.,<br />
Winthontlaan 200,<br />
3526 KV Utrecht,<br />
Holland </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>AT / BE / BG / CY / CZ / DE / DK / EE / FI / FR / HR / HU / IS / IT / LT / LV / LX / MT / NL / NO 
/ PT / PL / RO / SE / SI / SK / UK(NI) / ES 
Accord Healthcare S.L.U. 
Tel: +34 93 301 00<br />
EL 
Win Medica Pharmaceutical S.A.<br />
Tel: +30 210 7488<br />
Denne indlægsseddel blev senest ændret </p>
<p>Andre informationskilder </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-987766e2219c5177d278b3430b3652be
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for orgovyx Package Leaflet for language en"
Description: "ePI document Bundle for orgovyx Package Leaflet for language en"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-987766e2219c5177d278b3430b3652be"
* entry[0].resource = composition-en-987766e2219c5177d278b3430b3652be

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp987766e2219c5177d278b3430b3652be"
* entry[=].resource = mp987766e2219c5177d278b3430b3652be
                            
                    
Instance: bundlepackageleaflet-da-987766e2219c5177d278b3430b3652be
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for orgovyx Package Leaflet for language da"
Description: "ePI document Bundle for orgovyx Package Leaflet for language da"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-987766e2219c5177d278b3430b3652be"
* entry[0].resource = composition-da-987766e2219c5177d278b3430b3652be

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp987766e2219c5177d278b3430b3652be"
* entry[=].resource = mp987766e2219c5177d278b3430b3652be
                            
                    



Instance: mp987766e2219c5177d278b3430b3652be
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product orgovyx"
Description: "orgovyx"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/22/1642/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"


* indication = "Orgovyx is indicated for the treatment of adult patients with advanced hormone-sensitive prostate"


* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"


* name
  * productName = "orgovyx"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#DK "DK"
    * jurisdiction = urn:iso:std:iso:3166#DK "DK"
    * language = urn:ietf:bcp:47#en  "en"




RuleSet: 987766e2219c5177d278b3430b3652beListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "orgovyx"

* status = #current
* mode = #working

* title = "List of all ePIs associated with orgovyx"

* subject = Reference(mpba62682d7a134bf3f9e55395558b6846)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#orgovyx "orgovyx"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-987766e2219c5177d278b3430b3652be) // orgovyx en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-987766e2219c5177d278b3430b3652be) // orgovyx da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-987766e2219c5177d278b3430b3652be
InstanceOf: List

* insert 987766e2219c5177d278b3430b3652beListRuleset
    